Icagen gains on pain program update

Icagen Inc. (NASDAQ:ICGN) gained $0.96 (79%) to $2.18 on Tuesday after it and Pfizer Inc. (NYSE:PFE) selected a compound for further clinical development in the partners' sodium channel program for pa...